Literature DB >> 7199409

Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.

J E Carlsen, T Kardel, T Hilden, M Tangø, J Trap-Jensen.   

Abstract

The purpose of this study was to evaluate the immediate central and peripheral haemodynamic effects of a new vasodilating agent P 1134, in hypertensive man. After oral administration of 25 mg P 1134, the maximal haemodynamic changes were (mean +/- 1 SEM): mean blood pressure fell from 121.8 +/- 6.5 to 80.5 +/- 7.8 mmHg, heart rate increased 24.2 +/- 4.5 beats/min, cardiac output rose 2.9 +/- 0.3 1/min and forearm blood flow increased 1.0 +/- 0.1 ml/100 ml tissue/min. Stroke volume increased 17.0 +/- 2.1 ml and the inotropic state of the heart as judged from systolic time intervals increased. Total peripheral resistance and forearm vascular resistance were both reduced by approx. 50%. Linear correlations were found between the serum concentration of P 1134 and the change in mean blood pressure and total peripheral resistance. Changes in the other parameters mentioned above occurred progressively with changes in mean blood pressure and total peripheral resistance. It can be concluded that P 1134 is a very potent hypotensive agent with a haemodynamic profile identical to that seen with vasodilators with preferably act on precapillary resistance vessels. Potency and maximal efficacy exceeds that of hydralazine and seems like that of minoxidil. P 1134 is remarkably free from side-effects apart from causing water retention as all other vasodilators. It can be administered orally as well as intravenously. This makes P 1134 a very interesting compound in the treatment of moderate to severe hypertension, and further studies are well-founded.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7199409     DOI: 10.1111/j.1475-097x.1981.tb00905.x

Source DB:  PubMed          Journal:  Clin Physiol        ISSN: 0144-5979


  22 in total

Review 1.  Potassium channel openers. Pharmacological effects and future uses.

Authors:  S Duty; A H Weston
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat.

Authors:  A Makino; K Ohuchi; K Kamata
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

3.  Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.

Authors:  J E Carlsen; H A Jensen; M Rehling; J O Lund; J Trap-Jensen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.

Authors:  A McBurney; P R Farrow; S Ainsworth; J W Ward
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

5.  The effects of long-acting pinacidil on intra-arterial blood pressure.

Authors:  M P Caruana; I Al-Khawaja; P Royston; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

6.  Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.

Authors:  E G Breen; D Mulhall; J A Keogh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Evidence that the mechanism of the inhibitory action of pinacidil in rat and guinea-pig smooth muscle differs from that of glyceryl trinitrate.

Authors:  K M Bray; D T Newgreen; R C Small; J S Southerton; S G Taylor; S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

8.  Acute haemodynamic effects of pinacidil in man.

Authors:  D P Nicholls; J G Murtagh; M E Scott; P Morton; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

9.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Pinacidil monotherapy for hypertension.

Authors:  J W Ward
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.